Fatigue, Dyspnea and Abnormal Blood Counts

Katherine Walsh, MD and Eric Kraut, MD

Ohio State University

Copyright of the American Society of Hematology, 2013. ISSN: 1931-6860.

VIII. BIBLIOGRAPHY

Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131:401-408.

Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587-3591.

Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1259.

Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193-207.

Parker CJ. Management of Paroxysmal Nocturnal Hemoglobinuria in the Era of Complement Inhibitory Therapy. Hematology Am Soc Hematol Educ Program. 2011;2011:21-29. Review.

Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore). 1997;76:63-93.

Ware RE, Pickens CV, DeCastro CM, Howard TA. Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes. Exp Hematol. 2001;29:1403-1409.

Weitz I, Meyers G, Lamy T, Cahn JY, Uranga MT, et al. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern Med J. 2013;43:298-307.

Weitz IC, Razavi P, Rochanda L, Zwicker J, Furie B, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012:130:361-368.

Have a question or comment about the ASH Teaching Cases? Please e-mail webmaster@hematology.org.